RVL Pharmaceuticals plc (RVLPQ)
OTCMKTS: RVLPQ · Delayed Price · USD
0.0005
0.00 (0.00%)
May 3, 2024, 12:00 AM EDT - Market closed
Company Description
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.
It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.
The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.
RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
RVL Pharmaceuticals plc
Country | United States |
Founded | 2000 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 125 |
Contact Details
Address: 400 Crossing Boulevard Bridgewater, New Jersey 08807 United States | |
Phone | (908) 809-1300 |
Stock Details
Ticker Symbol | RVLPQ |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001739426 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Brian A. Markison | Chairman, President, Chief Executive Officer and Principal Financial Officer |
James D. Schaub | Executive Vice President and Chief Operating Officer |
Christopher A. Klein | General Counsel |
Michael J. DePetris | Principal Accounting Officer |
Jarret Miller | Executive Vice President of Human Resources |
Scott Schroppe | Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 13, 2024 | 8-K | Current Report |
Jan 17, 2024 | 8-K | Current Report |
Dec 20, 2023 | 8-K | Current Report |
Nov 28, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 27, 2023 | 8-K | Current Report |
Nov 20, 2023 | 25-NSE | Filing |
Nov 16, 2023 | DEF 14A | Other definitive proxy statements |
Nov 6, 2023 | PRE 14A | Other preliminary proxy statements |
Nov 6, 2023 | 8-K | Current Report |
Nov 1, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |